Please assess the completion status of the following clinical trial:

Trial Title: Glutamine for the Treatment of Patients With Irritable Bowel Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* men and women age 18-72 years old who developed post-infectious diarrhea-predominant IBS (D-IBS)~* increased intestinal permeability on Lactulose/Mannitol permeability test~* able and willing to cooperate with the study~* \*absence of alcohol or NSAIDs ingestion for 2 weeks prior to inclusion into study and throughout the study duration~Exclusion Criteria:~* current participation in another research protocol or unable to give informed consent~* women with a positive urine pregnancy test or breastfeeding~* history of inflammatory bowel disease, lactose intolerance, and/or celiac sprue~* + hydrogen breath test for bacterial overgrowth~* + antiendomysial antibody titer~* use of nonsteroidal antinflammatory drug(NSAIDs) 2 weeks before or during the study~* known allergy to glutamine~* abdominal surgery except for removal of gallbladder, uterus, or appendix~* Abnormal blood urea nitrogen(BUN) and/or creatinine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 72 Years
- Healthy Volunteers: f

Study Arms:
- Glutamine supplementation (Type: ACTIVE_COMPARATOR): Glutamine
- Placebo (Type: PLACEBO_COMPARATOR): Whey protein powder

Based on this trial design, predict the completion outcome and termination type (if applicable).